Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company investor relations website and will be archived for replay after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RPID declined 1.18%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $141M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RPID gained 10.46% while close peers were mixed: OWLT -5.63%, SERA -1.33%, PROF +1.31%, LNSR +1.96%, RCEL flat. This points to a stock-specific move rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Growth capital financing | Positive | +5.3% | $45M Trinity Capital commitment to scale Growth Direct and expansion. |
| Nov 07 | Earnings and guidance | Positive | +12.7% | Q3 2025 results with revenue growth and raised full-year guidance. |
| Oct 30 | Conference participation | Neutral | +1.4% | Participation in Stifel 2025 Healthcare Conference with webcast access. |
| Oct 28 | Earnings date notice | Neutral | -1.4% | Announcement of timing for Q3 2025 financial results webcast. |
| Sep 22 | Growth capital financing | Positive | -0.9% | $45M Trinity Capital growth capital to expand Growth Direct platform. |
Positive funding and earnings updates have often coincided with favorable next-day moves, while one growth-capital headline saw a small negative reaction.
Over the last several months, RPID has reported multiple financing and operating milestones. A Trinity Capital growth capital commitment of $45 million and subsequent details on a $45.0 million loan facility framed its balance sheet strategy. Q3 2025 results showed revenue of $7.8 million and raised full-year guidance to at least $33.0 million. Conference participation, such as the Stifel 2025 Healthcare Conference, has provided added visibility. Today’s J.P. Morgan conference appearance fits this pattern of emphasizing growth, commercial scaling, and investor outreach.
Market Pulse Summary
This announcement highlights RPID’s participation in a major healthcare investor conference, providing a platform to reiterate its strategy and recent milestones such as growth capital arrangements and updated revenue guidance. Past news flow has emphasized scaling the Growth Direct platform, manufacturing efficiency, and balance sheet support. Investors may focus on any new color shared at the event regarding commercial traction, cost structure, and progress against previously disclosed financing terms and operational targets.
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
The Company is scheduled to present on Thursday, January 15, 2026, at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) present at the J.P. Morgan Healthcare Conference?
How can investors watch the RPID presentation at the J.P. Morgan conference?
What is the ticker symbol for Rapid Micro Biosystems presenting on January 15, 2026?
Will the RPID webcast from the J.P. Morgan Healthcare Conference be available after the event?
What time is the RPID presentation in Pacific Time at the J.P. Morgan conference?
Where can I find the RPID webcast link for the January 15, 2026 presentation?
